Eli Lilly Earnings: What To Look For From LLY

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what investors should know.

Eli Lilly beat analysts’ revenue expectations by 0.9% last quarter, reporting revenues of $12.73 billion, up 45.2% year on year. It was a slower quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and a miss of analysts’ EPS estimates.

Is Eli Lilly a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Eli Lilly’s revenue to grow 30.6% year on year to $14.76 billion, slowing from the 36% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.59 per share.

Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 12 analysts). Eli Lilly has missed Wall Street’s revenue estimates four times over the last two years.

Looking at Eli Lilly’s peers in the branded pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Supernus Pharmaceuticals’s revenues decreased 1.7% year on year, beating analysts’ expectations by 7.4%, and Bristol-Myers Squibb reported flat revenue, topping estimates by 7.8%. Bristol-Myers Squibb traded down 3.9% following the results.

Read our full analysis of Supernus Pharmaceuticals’s results here and Bristol-Myers Squibb’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the branded pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Eli Lilly is down 1.1% during the same time and is heading into earnings with an average analyst price target of $956.67 (compared to the current share price of $764.25).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.